Comparative Pharmacology
Head-to-head clinical analysis: DEPACON versus MYSOLINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DEPACON versus MYSOLINE.
DEPACON vs MYSOLINE
Head-to-head clinical comparison of therapeutic indices and safety profiles.
Increases GABA concentration in the brain by inhibiting GABA transaminase and blocking voltage-gated sodium channels.
Primidone is a barbiturate anticonvulsant that acts by enhancing GABA-A receptor activity and possibly by blocking sodium channels.
Monotherapy and adjunctive therapy in complex partial seizuresAdjunctive therapy in absence seizuresProphylaxis of migraine headaches (off-label)Bipolar disorder maintenance (off-label)
FDA-approved: monotherapy or adjunctive treatment of generalized tonic-clonic seizures, complex partial seizures, and psychomotor seizuresOff-label: essential tremor
10-15 mg/kg/day IV or orally divided every 8 hours; maximum 60 mg/kg/day.
250 mg orally 3 times daily; may increase by 250 mg/day every 3 days; usual maintenance 250 mg 3-4 times daily; maximum daily dose 1500 mg.
None Documented
None Documented
10–16 hours; neonates 20–30 hours; patients with liver disease up to 18 hours; decreased half-life in patients on enzyme-inducing antiepileptics (e.g., phenytoin, carbamazepine) to 4–9 hours.
Primidone: 5-15 hours (mean 10 hours); PEMA: 10-18 hours; Phenobarbital: 50-120 hours. Steady state achieved in 2-4 weeks due to accumulation of phenobarbital.
Metabolized primarily via glucuronidation (CYP-independent) and beta-oxidation; less than 3% excreted unchanged in urine.
Primidone is metabolized primarily by the liver via CYP2C9 and CYP2E1 to two active metabolites: phenobarbital and phenylethylmalonamide.
Primarily renal: >90% of a dose is excreted in urine as valproic acid glucuronide (30–50%), 3-oxo-valproic acid (30–40%), and other metabolites. Less than 3% excreted unchanged. Minor fecal elimination (≈5%).
Primidone is excreted primarily in urine; approximately 60-80% as unchanged drug and metabolites (PEMA, phenobarbital), with less than 10% in feces.
90–95% bound to albumin; binding is saturable and decreased in uremia, hypoalbuminemia, and in elderly patients.
Primidone: 20-30%; phenobarbital: 45-60%. Primidone binds to plasma proteins, mainly albumin.
0.13–0.23 L/kg; increases with age and obesity; small Vd indicates predominant distribution in plasma and extracellular fluid.
Primidone: 0.6-1.0 L/kg (approx 42-70 L in 70 kg adult), indicating distribution into total body water.
Oral (immediate-release): ~100%; IV: 100%; rectal administration (not standard): approximately 80%.
Oral: 90-100%; food does not significantly affect absorption.
GFR 30-60 mL/min: reduce dose by 30%; GFR 15-29 mL/min: reduce dose by 50%; GFR <15 mL/min: avoid use or reduce dose by 70%.
CrCl <50 mL/min: not recommended; CrCl 50-80 mL/min: administer every 12 hours; CrCl >80 mL/min: usual dosing.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 30%; Child-Pugh C: reduce dose by 50%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 25-50%; Child-Pugh C: contraindicated.
10-20 mg/kg/day IV or orally divided every 6-8 hours; maximum 40 mg/kg/day.
>8 years: 10-20 mg/kg/day in 2-3 divided doses; <8 years: 10-15 mg/kg/day in 2-3 divided doses; maximum 1500 mg/day.
Start at lowest dose (10 mg/kg/day) and titrate slowly; monitor renal function and adjust accordingly.
Start at 250 mg once daily; increase slowly; monitor for sedation and ataxia.
Hepatotoxicity: Cases of life-threatening hepatic failure, especially in children under 2 years and patients with mitochondrial disease; fatalities reported. Contraindicated in patients with known liver disease.
Barbiturates are habit-forming. Tolerance, psychological and physical dependence may occur. Withdrawal symptoms (including seizures, hallucinations, and death) may occur after abrupt discontinuation. Use in pregnancy may cause fetal harm.
["Hepatotoxicity: Monitor liver function tests before and during therapy; discontinue if significant elevation.","Pancreatitis: Rare but potentially fatal; discontinue if pancreatitis suspected.","Hyperammonemic encephalopathy: Often in patients with urea cycle disorders or concomitant medications; monitor ammonia levels.","Teratogenicity: Valproate exposure causes neural tube defects and neurodevelopmental disorders; avoid in women of childbearing potential unless ineffective alternatives.","Thrombocytopenia and coagulation disorders: Platelet count and bleeding time monitoring recommended."]
May cause somnolence, dizziness, and ataxia; avoid abrupt withdrawal; monitor for hypersensitivity reactions; use with caution in hepatic or renal impairment; may exacerbate porphyria.
["Known hypersensitivity to valproate","Active liver disease or hepatic dysfunction","Urea cycle disorders","Women of childbearing potential (unless alternative treatments ineffective or benefits outweigh risks)"]
Absolute: hypersensitivity to primidone, barbiturates, or any component; porphyria; respiratory depression; severe hepatic impairment.
Data Pending Review
Data Pending Review
Take with food or milk to reduce gastrointestinal upset. Avoid grapefruit juice as it may increase valproate levels. Limit intake of foods high in aspartame (may increase ammonia levels). Maintain adequate hydration to reduce risk of hyperammonemia.
No specific food interactions are documented. However, alcohol consumption is contraindicated due to additive CNS depression and increased seizure risk.
Valproate (Depacon) is highly teratogenic. First trimester exposure is associated with a 3-4% risk of neural tube defects (spina bifida), as well as craniofacial defects, cardiac defects, and hypospadias. Second and third trimester exposure may be linked to neurodevelopmental disorders including autism spectrum disorder and low IQ. Risk is dose-dependent.
First trimester: Increased risk of major congenital malformations including orofacial clefts, cardiac defects, and neural tube defects (3-5x baseline). Second and third trimesters: Risk of neonatal hemorrhage (vitamin K-dependent clotting factors), hypocalcemia, and withdrawal symptoms. Chronic exposure: Possible neurodevelopmental delays.
Valproate is excreted into breast milk with a milk-to-plasma (M/P) ratio of approximately 0.05-0.1. Infant serum levels are low (1-10% of maternal levels). The American Academy of Pediatrics considers it compatible with breastfeeding. However, monitor for potential adverse effects such as hepatic dysfunction or thrombocytopenia in the infant.
Primidone enters breast milk; M/P ratio approximately 0.6-1.0. Infant serum levels can reach therapeutic ranges. Monitor for sedation, irritability, and poor feeding. Use with caution; avoid if possible in breastfeeding.
Pregnancy may alter valproate pharmacokinetics. Clearance increases in the second and third trimesters due to enhanced hepatic metabolism and volume expansion, leading to decreased serum concentrations. Dose adjustments (increasing dose) are often required to maintain therapeutic levels. Close monitoring of serum concentrations is recommended, especially after delivery when clearance decreases.
Increased clearance by 30-50% due to enhanced hepatic metabolism and plasma volume expansion. Monitor serum primidone and phenobarbital levels (active metabolite) every 4-6 weeks; adjust dose to maintain therapeutic levels. Dose increases of 20-30% may be required, especially in third trimester. Postpartum return to prepregnancy dose over 2-4 weeks.
Category C
Category C
Depacon (valproate sodium) injection is a prodrug of valproic acid. For status epilepticus, administer IV push at 20 mg/kg, then 1-3 mg/kg/h infusion. Avoid in liver disease; monitor liver enzymes and ammonia. Also used off-label for migraine prophylaxis and bipolar disorder maintenance.
MYSOLINE (primidone) is a barbiturate anticonvulsant metabolized to phenobarbital and PEMA. Its therapeutic drug monitoring should measure phenobarbital levels (target 15-40 mcg/mL). Avoid in porphyria and pregnancy. Monitor for sedation, ataxia, and nystagmus. Coadministration with valproate increases phenobarbital levels; adjust dose accordingly. Taper slowly to prevent withdrawal seizures.
Do not stop taking Depacon suddenly without consulting your doctor.Avoid alcohol while using this medication.Report any signs of liver injury (jaundice, abdominal pain, dark urine) or pancreatitis (severe abdominal pain, nausea, vomiting).Depacon may cause dizziness or drowsiness; avoid driving until you know how it affects you.If you are pregnant or planning to become pregnant, discuss risks; Depacon can cause birth defects.
Take exactly as prescribed; do not stop suddenly without medical advice as withdrawal seizures may occur.May cause drowsiness or dizziness; avoid driving or operating machinery until you know how this medication affects you.Avoid alcohol as it can increase sedation and risk of seizures.Use effective contraception during treatment; inform your doctor if you become pregnant or plan to become pregnant.Report any rash, fever, or unusual bruising/bleeding to your healthcare provider immediately.Take with food or milk if gastrointestinal upset occurs.Keep all appointments for blood tests to monitor medication levels.